The Protein Profile of the Human Immature T-cell Line CCRF-CEM.

The human immature T-cell line CCRF-CEM is widely used for all kinds of in vitro studies in biochemistry, biology, toxicology and medicine. Knowledge about protein expression is limited and no comprehensive study on the proteome of this cell type has been reported to date. Proteomics technologies were applied in order to analyse the proteins of the CEM cell line. The proteins were separated by two-dimensional (2-D) gel electrophoresis and analysed by MALDI-MS and MALDI-MS-MS following in-gel digestion with trypsin and, finally, protein identification was carried out by peptide mass fingerprint (PMF) and post source decay (PSD), respectively. Approximately 4,500 spots, excised from four 2-D gels, were analysed. The analysis resulted in the identification of about 1,150 proteins, the products of 451 different genes. The majority of the identified proteins were enzymes, regulatory proteins and transporters, while leukocyte markers and oncogenes were also included. The CCRF-CEM cell database today represents one of the largest 2-D databases for eukaryotic proteomes, forming the basis for future expressional studies at the protein level.

[1]  S. Corey,et al.  The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. , 1996, Blood.

[2]  G. Tsangaris,et al.  Protein profile of the HeLa cell line. , 2004, Journal of chromatography. A.

[3]  Ioannis Politis,et al.  Evaluation of cadmium-induced transcriptome alterations by three color cDNA labeling microarray analysis on a T-cell line. , 2002, Toxicology.

[4]  H. Lazarus,et al.  Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia , 1965, Cancer.

[5]  G. Tsangaris,et al.  Cadmium induces apoptosis differentially on immune system cell lines. , 1998, Toxicology.

[6]  Gert Lubec,et al.  Proteomics in brain research: potentials and limitations , 2003, Progress in Neurobiology.

[7]  David Bernhard,et al.  p53-induced apoptosis in the human T-ALL cell line CCRF-CEM , 1997, Oncogene.

[8]  J. Mangum,et al.  Inosine monophosphate dehydrogenase and myeloid cell maturation. , 1987, Blood.

[9]  P. Halada,et al.  Application of Proteomics in the Search for Novel Proteins Associated with the Anti-cancer Effect of the Synthetic Cyclin-dependent Kinases Inhibitor, Bohemine , 2002, Technology in cancer research & treatment.

[10]  S. Raimondi,et al.  The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1. , 1996, Oncogene.

[11]  Javier León,et al.  Inhibitory effect of c-Myc on p53-induced apoptosis in leukemia cells. Microarray analysis reveals defective induction of p53 target genes and upregulation of chaperone genes , 2005, Oncogene.

[12]  N. Curtin,et al.  The impact of p53 status on cellular sensitivity to antifolate drugs. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  Ning Zhang,et al.  High Throughput Proteome Screening for Biomarker Detection* , 2005, Molecular & Cellular Proteomics.

[14]  S. Pichuantes,et al.  Isolation of the human PC6 gene encoding the putative host protease for HIV-1 gp160 processing in CD4+ T lymphocytes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[15]  P Berndt,et al.  Reliable automatic protein identification from matrix‐assisted laser desorption/ionization mass spectrometric peptide fingerprints , 1999, Electrophoresis.

[16]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[17]  Z. Damuni,et al.  The Myeloid Leukemia-associated Protein SET Is a Potent Inhibitor of Protein Phosphatase 2A (*) , 1996, The Journal of Biological Chemistry.

[18]  Y. Liu,et al.  Comparison of bax, waf1, and IMP dehydrogenase regulation in response to wild‐type p53 expression under normal growth conditions , 1998, Journal of cellular physiology.

[19]  G. Lubec,et al.  Rat brain proteins: Two‐dimensional protein database and variations in the expression level , 1999, Electrophoresis.

[20]  Javier León,et al.  c-Myc antagonizes the effect of p53 on apoptosis and p21WAF1 transactivation in K562 leukemia cells , 2000, Oncogene.

[21]  Metallothionein expression prevents apoptosis: a study with antisense phosphorothioate oligodeoxynucleotides in a human T cell line. , 1998, Anticancer research.

[22]  M. Fountoulakis.  Proteomics: Current technologies and applications in neurological disorders and toxicology , 2001, Amino Acids.

[23]  T. Copeland,et al.  Identification and characterization of SET, a nuclear phosphoprotein encoded by the translocation break point in acute undifferentiated leukemia. , 1994, The Journal of biological chemistry.

[24]  G. Lubec.  Protein Expression in Down Syndrome Brain , 2001, Springer Vienna.

[25]  Y. Samstag,et al.  Actin cytoskeletal dynamics in T lymphocyte activation and migration , 2003, Journal of leukocyte biology.

[26]  L. Devy,et al.  P53 protein expression in human multidrug-resistant CEM lymphoblasts. , 1997, Leukemia research.

[27]  S. Shimohama,et al.  Proteomic Profiling and Neurodegeneration in Alzheimer's Disease , 2002, Neurochemical Research.

[28]  G. Lubec,et al.  Changes in the brain protein levels following administration of kainic acid , 2001, Electrophoresis.

[29]  S Farber,et al.  Morphologic variations in human leukemic lymphoblasts (CCRF‐CEM cells) after long‐term culture and exposure to chemotherapeutic agents: A study with the electron microscope , 1966, Cancer.

[30]  G. Tsangaris,et al.  Cadmium Induces Fas Down-Regulation in a Human Immature T-cell Line. , 2004, Cancer genomics & proteomics.

[31]  B Johansson,et al.  Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations , 2005, Leukemia.

[32]  M. Fountoulakis,et al.  Application of proteomics technologies in the investigation of the brain. , 2004, Mass spectrometry reviews.

[33]  D N Shapiro,et al.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.

[34]  M. Horikoshi,et al.  Purification, crystallization and preliminary X-ray crystallographic analysis of human CCG1-interacting factor B. , 2000, Acta crystallographica. Section D, Biological crystallography.

[35]  P. Halada,et al.  Proteomics approach in classifying the biochemical basis of the anticancer activity of the new olomoucine‐derived synthetic cyclin‐dependent kinase inhibitor, bohemine , 2000, Electrophoresis.

[36]  T. Hayakawa,et al.  Possible involvement of optimally phosphorylated L-plastin in activation of superoxide-generating NADPH oxidase. , 2003, Journal of biochemistry.

[37]  J. Salmon,et al.  Detection of human leukemia cells with multidrug-resistance phenotype using multilabeling with fluorescent dyes. , 1993, Anticancer research.

[38]  Y. Hayashi,et al.  SEPTIN6, a human homologue to mouse Septin6, is fused to MLL in infant acute myeloid leukemia with complex chromosomal abnormalities involving 11q23 and Xq24. , 2002, Cancer research.

[39]  Gert Lubec,et al.  Aberrant expression of peroxiredoxin subtypes in neurodegenerative disorders , 2003, Brain Research.

[40]  S. Pittman,et al.  Resistance to apoptotic cell death in a drug resistant T cell leukaemia cell line. , 1996, Leukemia.

[41]  B. Lynn,et al.  Identification of Nucleophosmin as an NF-κB Co-activator for the Induction of the Human SOD2 Gene* , 2004, Journal of Biological Chemistry.